Pubertal and Gonadal Outcomes in 46,XY Individuals with Partial Androgen Insensitivity Syndrome Raised as Girls.

Androgen insensitivity syndrome Differences of sex development Disorders of sex development Partial androgen insensitivity syndrome Puberty

Journal

Sexual development : genetics, molecular biology, evolution, endocrinology, embryology, and pathology of sex determination and differentiation
ISSN: 1661-5433
Titre abrégé: Sex Dev
Pays: Switzerland
ID NLM: 101316472

Informations de publication

Date de publication:
2023
Historique:
received: 14 01 2022
accepted: 06 09 2022
medline: 9 8 2023
pubmed: 15 3 2023
entrez: 14 3 2023
Statut: ppublish

Résumé

Although it was common in the 1970s-1990s to assign female gender of rearing to 46,XY infants with limited virilization of varying etiologies, including those with partial androgen insensitivity syndrome (PAIS), long-term data on outcomes for these individuals are sparse. Therefore, our goal was to use the power of an international registry to evaluate clinical features, surgical management, and pubertal data in patients with a molecularly confirmed diagnosis of PAIS who were born before 2008 and were raised as girls. The current study interrogated the International Disorders of Sex Development Registry for available data on management and pubertal outcomes in individuals with genetically confirmed PAIS who were raised as girls. Among the 11 individuals who fulfilled the key criteria for inclusion, the external masculinization score (EMS) at presentation ranged from 2 to 6 (median 5); 7 girls underwent gonadectomy before the age of 9 years, whereas 4 underwent gonadectomy in the teenage years (≥ age 13). Clitoral enlargement at puberty was reported for 3 girls (27%) who presented initially at the time of puberty with intact gonads. In the 9 individuals (82%) for whom gonadal pathology data were provided, there was no evidence of germ cell tumor at median age of 8.1 years. All girls received estrogen replacement, and 8/11 had attained Tanner stage 4-5 breast development at the last assessment. In general, although it appears that female assignment in PAIS is becoming uncommon, our data provide no evidence to support the practice of prophylactic prepubertal gonadectomy with respect to the risk of a germ cell tumor.

Identifiants

pubmed: 36917969
pii: 000526997
doi: 10.1159/000526997
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

16-25

Subventions

Organisme : Medical Research Council
ID : G1100236
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom

Informations de copyright

© 2023 S. Karger AG, Basel.

Auteurs

Guilherme Guaragna-Filho (G)

Department of Pediatrics, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.

Gil Guerra-Junior (G)

Interdisciplinary Group for Study of Sex Determination and Differentiation (GIEDDS), State University of Campinas, Campinas, Brazil.

Rieko Tadokoro-Cuccaro (R)

Department of Paediatrics, University of Cambridge, Cambridge, UK.

Ieuan A Hughes (IA)

Department of Paediatrics, University of Cambridge, Cambridge, UK.

Beatriz A Barros (BA)

Interdisciplinary Group for Study of Sex Determination and Differentiation (GIEDDS), State University of Campinas, Campinas, Brazil.

Olaf Hiort (O)

Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics and Adolescent Medicine, University of Lübeck, Lübeck, Germany.

Antonio Balsamo (A)

Department of Medical and Surgical Sciences, Pediatric Unit, Center for Rare Endocrine Conditions (Endo-ERN), S.Orsola-Malpighi University Hospital, Bologna, Italy.

Tulay Guran (T)

Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, School of Medicine, Marmara University, Istanbul, Turkey.

Paul M Holterhus (PM)

Department of Pediatrics, Pediatric Endocrinology and Diabetes, University Hospital of Schleswig-Holstein, UKSH, Campus Kiel, Kiel, Germany.

Sabine Hannema (S)

Department of Paediatrics, Leiden University Medical Centre, Leiden, The Netherlands.
Expertise Center DSD and Department of Paediatric Endocrinology, Sophia Children's Hospital, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands.

Sukran Poyrazoglu (S)

Department of Pediatrics, Pediatric Endocrinology Unit, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.

Feyza Darendeliler (F)

Department of Pediatrics, Pediatric Endocrinology Unit, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.

Jillian Bryce (J)

Office for Rare Conditions, University of Glasgow, Glasgow, UK.

S Faisal Ahmed (SF)

Office for Rare Conditions, University of Glasgow, Glasgow, UK.
Developmental Endocrinology Research Group, University of Glasgow, Glasgow, UK.

Charmian A Quigley (CA)

Department of Endocrinology, Sydney Children's Hospital, Randwick, New South Wales, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH